There's nothing boring about boron at Anacor Pharmaceuticals (NASDAQ:ANAC). Boron-based compounds have a unique geometry that allows them to have two distinct shapes. Boron's reactivity also allows it to interact with biological targets in unique ways. This means that boron-based drugs have the potential to interact with biological targets in ways that carbon-based compounds can't. At least that's the basis behind all eight of Anacor's clinical stage candidates.
Anacor scientists are experts at synthesizing boron-based compounds that react with their intended targets while minimizing unwanted activity. One of Anacor's targets is the fungal enzyme, leucyl transfer RNA synthetase ((LeuRS)). This enzyme is necessary for protein synthesis in dermatophytes, or the fungi that infect skin, hair, or nails. Let's...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|